Research location
Blackfoot
Idaho, United States
Advertisement
Research activity in Blackfoot
Idaho, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 50 trials and 50 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Blackfoot
50 linked trials · page 1 of 1A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood SugarNCT07754461 · 2026-08-24 · 1 site observation
RECRUITING
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related ComorbiditiesNCT07752979 · 2026-08-04 · 1 site observation
RECRUITING
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 DiabetesNCT07415954 · 2026-04-17 · 1 site observation
RECRUITING
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainNCT07481630 · 2026-04-13 · 1 site observation
RECRUITING
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesNCT07351058 · 2026-03-23 · 1 site observation
RECRUITING
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightNCT07400107 · 2026-05-20 · 1 site observation
NOT_YET_RECRUITING
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 DiabetesNCT06901349 · 2025-05-23 · 1 site observation
WITHDRAWN
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT06649045 · 2024-10-22 · 1 site observation
COMPLETED
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 DiabetesNCT06326047 · 2024-03-18 · 1 site observation
COMPLETED
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass PreservationNCT06299098 · 2024-03-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)NCT06269107 · 2024-02-15 · 1 site observation
COMPLETED
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant HypertensionNCT06153693 · 2023-11-22 · 1 site observation
COMPLETED
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 InhibitorNCT06109311 · 2023-11-10 · 1 site observation
COMPLETED
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeNCT05931367 · 2023-08-01 · 1 site observation
COMPLETED
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With HypertensionNCT05968430 · 2023-07-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT05869903 · 2023-06-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseNCT05882045 · 2023-05-30 · 1 site observation
COMPLETED
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskNCT05803421 · 2023-04-03 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityNCT05556512 · 2022-10-11 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily InjectionsNCT05462756 · 2022-08-11 · 1 site observation
COMPLETED
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 DiabetesNCT05478252 · 2022-08-03 · 1 site observation
COMPLETED
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related ComorbiditiesNCT05051579 · 2021-09-29 · 1 site observation
COMPLETED
A Study of LY3437943 in Participants With Type 2 DiabetesNCT04867785 · 2021-05-13 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss ProgramNCT04657016 · 2021-03-29 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are OverweightNCT04657003 · 2021-03-29 · 1 site observation
COMPLETED
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)NCT04795531 · 2021-03-24 · 1 site observation
COMPLETED
A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin BeforeNCT04760626 · 2021-03-01 · 1 site observation
COMPLETED
Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 DiabetesNCT04707469 · 2021-01-15 · 1 site observation
COMPLETED
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin BeforeNCT04460885 · 2020-11-25 · 1 site observation
COMPLETED
A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes MellitusNCT04450394 · 2020-07-01 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT04255433 · 2020-05-29 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 DiabetesNCT03987919 · 2019-07-30 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 DiabetesNCT03882970 · 2019-04-01 · 1 site observation
COMPLETED
A Study of LY3209590 in Participants With Type 2 Diabetes MellitusNCT03736785 · 2018-11-15 · 1 site observation
COMPLETED
A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 DiabetesNCT03495102 · 2018-04-05 · 1 site observation
COMPLETED
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With MetforminNCT03351478 · 2017-11-27 · 1 site observation
COMPLETED
A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 DiabetesNCT03214380 · 2017-07-14 · 1 site observation
COMPLETED
A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic DrugsNCT03078478 · 2017-03-13 · 1 site observation
COMPLETED
LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.NCT02964247 · 2017-03-03 · 1 site observation
COMPLETED
A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin MonotherapyNCT02973100 · 2016-12-01 · 1 site observation
COMPLETED
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.NCT02849080 · 2016-09-20 · 1 site observation
COMPLETED
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise OnlyNCT02906930 · 2016-09-20 · 1 site observation
COMPLETED
A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes MellitusNCT02501161 · 2016-01-31 · 1 site observation
COMPLETED
The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic NeuropathyNCT02643251 · 2015-12-01 · 1 site observation
COMPLETED
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes MellitusNCT02420262 · 2015-07-26 · 1 site observation
COMPLETED
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)NCT02451137 · 2015-06-16 · 1 site observation
COMPLETED
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration AlgorithmsNCT02298192 · 2014-11-21 · 1 site observation
COMPLETED
Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and MetforminNCT01907854 · 2013-12-02 · 1 site observation
COMPLETED
Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the NervesNCT01939366 · 2013-09-27 · 1 site observation
COMPLETED
Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 HypertensionNCT01508026 · 2012-01-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.